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benefit and toxicity of the addition of radiotherapy over hormones 
alone in this group. 
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Purpose/Objective: Prostate cancer patients (pts) under 70 years are 
more often candidates to surgery rather than radiotherapy (RT). We 
analyzed the results of ≤ 70 years patients with localized disease to 
demonstrate that RT is a valid alternative to surgery also in younger 
men.  
Materials and Methods: From January 1988 to December 2009, 214 
pts with T1-2N0M0 prostate cancer were treated with 3-5 fields 
conformal RT. The median baseline PSA level was 10,4 ng/ml (range 
0.2–254), Gleason score (GS) was: 2-6 in 114 pts, 7 in 37 pts, and 8-10 
in 18 pts. During the years the dose to the prostate was gradually 
increased from 60 Gy to 76 Gy. Forty-eight pts (22,4%) received 60-68 
Gy and 166 (77,6%) 70-76 Gy in 2 Gy daily fractions. Biochemical 
failure was defined according to ASTRO consensus criteria. Acute and 
late toxicity were graded according to the RTOG and EORTC criteria. 
Moreover we investigated the effects of patient and treatment related 
risk factors on acute and late toxicity.  
Results: The median follow-up was 105 months (range 14.2-180). 
Biochemical relapse occurred in 65 pts (30.4%), local failure in 8 
(3.7%), regional failure in 2 (0.9 %), distant metastases in 20 (9.3 %). 
The 5 and 10 year biochemical relapse free survival (bRFS) for all 214 
pts were 80 and 61.9% respectively. In univariate analysis initial PSA 
(≤10 vs>10 ng/ml, p=0.006) and PSA nadir (< 1 vs ≥ 1 ng/ml, p=0.023) 
but not age (≤ 65 vs 65-70 years) were significant factors for 
biochemical relapse. The 5 and 10 years bRFS were 84.4% and 66.7% 
when PSA nadir was <1 ng/ml, 60.9% and 43% respectively, when it 
was ≥ 1 ng/ml ( p<0.001). In multivariate analysis risk factors for 
biochemical relapse were initial PSA value ( p<0.001) and radiation 
dose (p=0.05). The mean cancer specific survival (CSS) of all pts was 
231.05 months. The CSS rate at 5 and 10 were 98.4 % and 93.2% 
respectively. In univariate analysis for CSS only PSA nadir was a 
significant factor (p<0.001). PSA nadir (p=0.019) and low radiation 
dose (p=0.037) were predictive for distant metastases in univariate 
analysis, while in multivariate analysis only initial PSA was significant 
(p=0.041). The median overall survival (OS) was160.2 months (range 
139.7-180.7). The OS rate at 5 and 10 were 91.8 % and 75.8% 
respectively.  
Acute genitourinary (GU) and gastrointestinal (GI) toxicities occurred 
in 105 (49%) and 98 pts (45.8%), respectively. There were no cases of 
Grade III or IV GU toxicity. There were 2 cases of Grade III GI toxicity . 
Late GU and GI toxicities occurred in 17(7.9%) and 20 (9.3%) patients 
respectively. There was one patient with Grade III GI toxicity and 2 
pts (0.9%) with Grade III GU. Risk factors for late toxicity were age 
and RT dose and technique while they were not related to acute 
toxicity.  
Conclusions: Age ≤ 70 years does not consistently confer a negative 
prognosis in pts with localized prostate cancer. RT appears to be a 
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Purpose/Objective: Theoretically, moderate dose escalation and 
prophylactic pelvic lymph-nodal area (PLNA) irradiation could reduce 
the incidence of treatment failures after salvage radiotherapy for 
biochemical failure (BF) following radical prostatectomy (RP). Aim of 
this study was to investigate the toxicity profile and the early clinical 
outcome of high dose moderately hypofractionated salvage 
Tomotherapy with PLNA irradiation. 
Materials and Methods: From 7/2007 to 12/2010, 65 patients (pts) 
with BF after radical prostatectomy underwent salvage Tomotherapy 
(TOMOSALV) to the prostatic bed (PB) and prophylactic PLNA 
irradiation. Patient characteristics: median age 67 years, iPSA 10.29 
ng/mL, pathologic stage pT2/pT3a/pT3b 51/8/6; pN0/pNx 57/8, 
median number of pelvic LN removed 10, positive surgical margins 36, 
Gleason score 2-6/7/8-10: 17/38/10. Median interval from RP to PSA 
failure 33.73 months (range 7-127); median PSA doubling time (PSADT) 
8.62 months (range 0.53-36.55), median pre-Tomotherapy PSA 
(PSA@RT) 0.36 ng/mL (range 0,17-8.49). In 6 patients local relapse 
was biopsy confirmed.  
All pts were treated with moderately hypofractionated (28 fractions) 
simultaneous integrated boost (SIB) technique. The dose to PLNA was 
51.8 Gy, 1.85 Gy/fraction. The seminal vesicles bed was always 
irradiated to 61.6 Gy (2.2 Gy/fraction), while the dose to the PB was 
71.4 Gy (72.8 in the case of biopsy confirmed relapse). 21 pts also 
received adjuvant androgen deprivation (AAD) for a median of 24 
months (range 3-37). 
Results: Median follow-up was 41 months. To date, all pts except one 
(death from gastric cancer 14 months after RT completion, bNED) are 
alive. Seven pts (median PSA@RT 0.42 ng/mL, median PSADT 5 
months) experienced BF (defined as a single PSA value >0.20 ng/mL 
after a post-radiotherapy nadir or a continuous rise despite 
irradiation) 25 months after Tomotherapy end and underwent salvage 
hormonotherapy. In 2 of these pts a clinical relapse (in both 
lumboaortic LN) was also observed. The 3-year biochemical relapse-
free survival (bRFS) was 91%, with no difference between patients 
receiving or not AAD (91% vs 90%) and with 4/7 relapsed patients who 
had received AAD. Acute toxicity: 5 Grade 2 (G2) GU, 4 G2 bowel and 
7 G2 proctitis. No G3 or G4.  
Late toxicity: G≥2 GU in 19 (29%), 8 G2, 11 G3. Grade ≥2 proctitis 7 
(11%), 3 G2 and 4 G3. Of note, thus far no Grade ≥2 bowel late 
sequelae have been observed. 
Conclusions: This study suggests that timely moderately 
hypofractionated high dose (EQD2 ≥74-76 Gy) TOMOSALV with 
prophylactic PLNA irradiation is feasible and burdened by only mild 
acute and late gastrointestinal side effects, while GU toxicity was not 
insignificant. 
The >90% 3-year bRFS compares more than favourably with the 
literature data, suggesting a possible benefit deriving from both PLNA 
irradiation and moderate dose escalation, though a more refined 
modelling of factors influencing GU toxicity is needed. 
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Purpose/Objective: To assess the impact of Choline-PET in treatment 
planning of prostate cancer (PCa) patients eligible for radiation 
therapy (RT). 
Materials and Methods: We prospectively enrolled 20 consecutive 
patients (mean age 70.4years, range 58-84) referred to our 
department for RT planning with radical intent (n=2) or assavage 
therapy (n=18). Patient were submitted to a single-day protocol, 
including dedicated CT scan of the pelvis and Choline-PET. Gross-
tumor volumes (GTV) , clinical-tumor volumes(CTV), planning-tumor 
volumes (PTV) and organs at risk (OAR) were outlined on CT with 
Eclipse Varian Medical System software, whereas GTV-PET was 
defined as areas with pathologic uptake and contoured with PETVCAR 
software on Adwantage GE workstation. 
Results: According to the imaging findings, in 14/20 patients the 
indication for RT was confirmed: in 2 cases it was limited to the 
prostatic bed, in 7 cases RT was extended to the entire pelvis, and in 
5 patients, treatment was performed on extra-pelvicorgans. In 30% of 
cases (6/20), either a negative scan or evidence of extensive disease 
at PET addressed patients to other treatment options. Overall 
Choline-PET determined a modification in patient management in 75% 
of cases(15/20): in 7 patient the impact was exerted directly in 
treated volumes, whereas a specific boost in PET-positive lesions was 
given to 50% of all irradiated patients (7/14). 
Conclusions: Choline-PET can have a significant impact on RT 
planning of PCa patients. The influence in therapeutic decision is seen 
up to 75% of cases, and in 1/3 of patients unnecessary RT can be 
avoided. 
 
 
 
 
 
 
